Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
52.15
-0.35 (-0.67%)
May 9, 2025, 5:35 PM CET
BIT:REC Revenue
Recordati Industria Chimica e Farmaceutica had revenue of 679.96M EUR in the quarter ending March 31, 2025, with 11.87% growth. This brings the company's revenue in the last twelve months to 2.41B, up 12.85% year-over-year. In the year 2024, Recordati Industria Chimica e Farmaceutica had annual revenue of 2.34B with 12.45% growth.
Revenue (ttm)
2.41B
Revenue Growth
+12.85%
P/S Ratio
4.49
Revenue / Employee
527.01K
Employees
4,583
Market Cap
10.83B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.34B | 259.23M | 12.45% |
Dec 31, 2023 | 2.08B | 229.02M | 12.36% |
Dec 31, 2022 | 1.85B | 273.23M | 17.29% |
Dec 31, 2021 | 1.58B | 131.21M | 9.06% |
Dec 31, 2020 | 1.45B | -32.98M | -2.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DiaSorin | 1.21B |
Amplifon | 2.42B |
Philogen | 77.65M |
EL.En. | 565.85M |
Pharmanutra | 116.15M |
Garofalo Health Care | 467.77M |
Safilo Group | 993.22M |
GPI S.p.A. | 509.93M |
Recordati Industria Chimica e Farmaceutica News
- 1 day ago - Recordati reports Q1 results - Seeking Alpha
- 1 day ago - RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2% - GlobeNewsWire
- 3 months ago - There is still such a huge need to do better with rare diseases: Recordati CEO - CNBC
- 5 months ago - Angelini Pharma Said to Discuss Combination With CVC’s Recordati - BNN Bloomberg
- 6 months ago - Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase - CNBC
- 6 months ago - Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus
- 6 months ago - Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Recordati reports nine-month results - Seeking Alpha